Reference : Zolmitriptan, a 5-HT1B/1D receptor agonist for the acute oral treatment of migraine: a m...
Scientific journals : Article
Human health sciences : Neurology
Social & behavioral sciences, psychology : Neurosciences & behavior
http://hdl.handle.net/2268/24463
Zolmitriptan, a 5-HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose-range finding study.
English
Dahlof, C. [> > > >]
Diener, H. C. [> > > >]
Goadsby, P. J. [> > > >]
Massiou, H. [> > > >]
Olesen, J. [> > > >]
Schoenen, Jean mailto [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Neuro-anatomie >]
Wilkinson, M. [> > > >]
Sweet, R. M. [> > > >]
Klein, K. B. [> > > >]
1998
European Journal of Neurology
Blackwell Science
5
6
535-543
Yes (verified by ORBi)
International
1351-5101
1468-1331
Oxford
United Kingdom
[en] Zolmitriptan is a selective 5-HT1B/1D receptor agonist for acute oral migraine therapy. This randomized, placebo-controlled, parallel-group study investigated the efficacy and tolerability of oral zolmitriptan (5, 10, 15 and 20 mg) in the treatment of single acute migraine attacks. Of 1181 patients randomized, 840 were evaluable for the primary efficacy analysis. Headache response rates (a reduction in headache intensity from severe or moderate at baseline to mild or no pain at 2 hours post-treatment) were similar across the zolmitriptan dose groups (66%, 71%, 69% and 77% for 5 mg, 10 mg, 15 mg and 20 mg, respectively) and were significantly higher than that for placebo (19%; all groups P < 0.001). A headache response was reported at 1 hour by 40-50% of zolmitriptan recipients (16% placebo). At 2 hours post dose, 39-47% of zolmitriptan-treated patients were pain-free, compared with 1% of placebo recipients. Headache recurrence occurred in 21-29% (upper 95% CI 37.1) of zolmitriptan-treated patients and in 65% (95% CI 38.3, 85.8) of placebo recipients. Zolmitriptan was well tolerated at each dose. The most commonly reported adverse events were asthenia, dizziness, paraesthesia and feelings of heaviness. Most adverse events were of mild or moderate intensity and were transient. The frequency of adverse events was dose-related. Although, zolmitriptan 5 mg exhibited the most favourable efficacy and tolerability profile, the dose response data suggest that lower doses would also offer significant efficacy. Copyright 1998 Lippincott Williams & Wilkins
http://hdl.handle.net/2268/24463

There is no file associated with this reference.

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.